Trial Profile
A Phase II, Multicenter, Adaptive-design Study to Assess the Safety and Efficacy of VM202RY Injected Via Percutaneous Transendocardial Route in Subjects With Acute Myocardial Infarction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2021
Price :
$35
*
At a glance
- Drugs Donaperminogene seltoplasmid (Primary)
- Indications Coronary artery disease; Ischaemic heart disorders; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Sponsors Helixmith
- 23 Oct 2019 Status changed from withdrawn prior to enrolment to recruiting.
- 16 Oct 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 18 Jan 2018 Status changed from planning to recruiting.